Human prostatic specific reductase

• US 6,344,198 B1
• Filed: 07/27/1998
• Issued: 02/05/2002
• Est. Priority Date: 01/20/1995
• Status: Expired due to Fees

• Current Assignee: Human Genome Sciences Incorporated (GlaxoSmithKline PLC)
• Original Assignee: Human Genome Sciences Incorporated (GlaxoSmithKline PLC)
• Inventors: He, Wei W., Rosen, Craig A., Meissner, Paul S., Hudson, Peter L.
• Primary Examiner(s): Caputa, Anthony C.
• Assistant Examiner(s): HUNT, JENNIFER ELIZABETH
• Application Number:
  US09/123,386
• Time in Patent Office: 1,289 Days
• Field of Search: 530/387.1, 530/387.7, 530/388.1, 530/388.15, 530/387.3, 530/388.8, 424/130.1, 424/133.1, 424/138.1, 424/139.1, 424/141.1, 424/142.1, 424/143.1, 424/152.1, 424/172.1, 424/174.1
• US Class Current: 424/139.1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: C12N 9/0004 Oxidoreductases (1.)
• CPC Class Codes: G01N 2500/04 Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Abstract

A human prostatic specific reductase polypeptide and polynucleotides encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polynucleotides as a diagnostic marker for prostate cancer and as an agent to determine if the prostate cancer has metastasized. Also disclosed are antibodies specific to the prostatic specific reductase polypeptide which may be used to target prostate cancer cells and be used as part of a prostate cancer vaccine. Methods of screening for agonists and antagonists for the polypeptide and therapeutic uses of the antagonists are also disclosed.

Claims

1. An antibody or portion thereof capable of specifically binding to a protein consisting of the amino acid sequence of SEQ ID NO:

2.

2. The antibody or portion thereof of claim 1 which is a monoclonal antibody.

3. The antibody or portion thereof of claim 1 which is a polyclonal antibody.

4. The antibody or portion thereof of claim 1 which is a chimeric antibody.

5. The antibody or portion thereof of claim 1 which is a humanized antibody.

6. The antibody or portion thereof of claim 1 which is an Fab fragment.

7. The antibody or portion thereof of claim 1 which is a single chain antibody.

8. The antibody or portion thereof of claim 1 which is immobilized.

9. The antibody or portion thereof of claim 1 which is labeled.

10. A composition comprising the antibody or portion thereof of claim 1 and a pharmaceutically acceptable carrier.

11. The composition of claim 10, wherein the antibody or portion thereof is a monoclonal antibody.

12. The composition of claim 10, wherein the antibody or portion thereof is humanized.

13. The composition of claim 10, wherein the carrier is saline.

14. The composition of claim 10, wherein the carrier is dextrose.

15. The composition of claim 10, wherein the carrier is water.

16. The composition of claim 10, wherein the carrier is glycerol.

17. A hybridoma cell line that produces the monoclonal antibody of claim 2.

18. The hybridoma cell line of claim 17 wherein the antibody or portion thereof is humanized.

19. An antibody or portion thereof capable of specifically binding to a protein consisting of the amino acid sequence that is encoded by the cDNA contained in ATCC Deposit No. 75913.

20. The antibody or portion thereof of claim 19 which is a monoclonal antibody.

21. The antibody or portion thereof of claim 19 which is a polyclonal antibody.

22. The antibody or portion thereof of claim 19 which is a chimeric antibody.

23. The antibody or portion thereof of claim 19 which is a humanized antibody.

24. The antibody or portion thereof of claim 19 which is an Fab fragment.

25. The antibody or portion thereof of claim 19 which is a single chain antibody.

26. The antibody or portion thereof of claim 19 which is immobilized.

27. The antibody or portion thereof of claim 19 which is labeled.

28. A composition comprising the antibody or portion thereof of claim 19 and a pharmaceutically acceptable carrier.

29. The composition of claim 28, wherein the antibody or portion thereof is a monoclonal antibody.

30. The composition of claim 29, wherein the antibody or portion thereof is humanized.

31. The composition of claim 28, wherein the carrier is saline.

32. The composition of claim 28, wherein the carrier is dextrose.

33. The composition of claim 28, wherein the carrier is water.

34. The composition of claim 28, wherein the carrier is glycerol.

35. A hybridoma cell line that produces the monoclonal antibody of claim 20.

36. The hybridoma cell line of claim 35 wherein the antibody or portion thereof is humanized.